Chile's CFR Pharmaceuticals faces one more obstacle in its bid for the South African drugmaker Adcock Ingram. After wooing Adcock for months, the Chilean company now faces stepped-up opposition from selling shareholders.
If you take a big bet on an up-and-coming pharmaceutical maker and you turn out to be right, you should be able to reap some profit from your investment. That's what GlaxoSmithKline ($GSK) intends to do with a third of its stake in Aspen Pharmacare, a fast-growing South African drugmaker that has had a partnership with GSK since 2009.
After reportedly striking out in an effort to find a buyer, Clovis Oncology has struck up a deal of its own, agreeing to buy Italy's Ethical Oncology Science and its mid-stage targeted cancer drug lucitanib for up to $420 million.
Royal DSM and Patheon will join in a deal valued at $2.6 billion that they say will make them a major force in the pharma services business.
Teva Pharmaceutical Industries has no CEO. Its stock price stinks, and in 6 months it could face generic competition for the drug that generates 20% of its revenues. It may be time for something dramatic, like a multibillion-dollar tie-up with another drugmaker that can save it from itself--a company like Actavis or Mylan.
CareFusion is handing over $500 million for GE Healthcare's Vital Signs arm, an acquisition it said will make it a giant in the respiratory and anesthesia consumables business but also fuel a broader global expansion.
CRO Medpace is on the block and could go for up to $1.2 billion, Reuters reports, as private equity owner CCMP Capital Advisors could be looking to cash out while the market for contract researchers remains bullish.
Merck KGaA is still crawling through a broad restructuring effort, but the German drugmaker said it's keeping an eye out for major deals that could help it piece together a promising pipeline after years of setbacks.
San Diego's Volcano is facing shareholder pressure to boost its value and find itself a buyer, and analysts believe the intravascular device company could be an ideal target for med tech giants Abbott Laboratories and Medtronic.
Two months after merging with ReSearch Pharmaceutical Services to form the world's fourth-largest CRO, PRA is back on the buyer's block, snatching up the early-stage-focused CRI Lifetree.